Drug Profile


Alternative Names: D-121; OIPC

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Max Planck Innovation
  • Developer Oblita Therapeutics
  • Class Antiparasitics; Phospholipids; Quaternary ammonium compounds
  • Mechanism of Action Cell division inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leishmaniasis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chagas disease; Cryptosporidiosis; Leishmaniasis; Mycoses

Most Recent Events

  • 24 Aug 2017 Chemical structure information added
  • 12 Feb 2016 Phase-I clinical trials in Chagas' disease in Belgium (PO) prior to February 2016
  • 12 Feb 2016 Phase-I clinical trials in Cryptosporidiosis in Belgium (PO) prior to February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top